BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides

Add time:07/12/2019    Source:sciencedirect.com

β-Secretase (BACE1) has been widely recognized as one of the possible therapeutic targets for the treatment of Alzheimer’s disease. In this paper, we report the synthesis and the BACE1 inhibitory activity of new, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides. Each enantiomeric form was separately evaluated in BACE1 inhibition assays and IC50 values were obtained in the low micromolar range. According to our biological results and docking studies, it can be asserted that the stereochemistry around the OH group in the central hydroxyethylamino linker does not significantly influence the BACE1 inhibitory activity of this type of molecules.

We also recommend Trading Suppliers and Manufacturers of 1-(CYCLOPROPYLMETHYL)PIPERAZINE 97 (cas 57184-25-5). Pls Click Website Link as below: cas 57184-25-5 suppliers

Prev:Structure of seven organic salts assembled from 2,6-diaminopyridine with monocarboxylic acids, dicarboxylic acids, and tetracarboxylic acids
Next:Analysis of mixtures of fatty acids and fatty alcohols in fermentation broth)